Case report

Berardinelli-Seip syndrome patient with novel AGPAT2 splicesite mutation and concomitant development of non-diabetic polyneuropathy

Short title: New AGPAT2 splicesite mutation with polyneuropathy.

Joanna Oswiecimska1, Mateusz Dawidziuk2, Tomasz Gambin3,2,4, Katarzyna Ziora1, Marta Marek5, Sylwia Rzonca2, D. Lys Guilbride6, Shalini N. Jhangiani7, Anna Obuchowicz5, Alicja Sikora5, James R. Lupski4,8,9, Wojciech Wiszniewski2,10, Pawel Gawlinski2
1Department of Pediatrics in Zabrze, Medical University of Silesia in Katowice, Poland
2Department of Medical Genetics, Institute of Mother and Child, Warsaw, Poland
3Institute of Computer Science, Warsaw University of Technology, Warsaw, Poland
4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
5Department of Pediatrics in Bytom, Medical University of Silesia in Katowice, Poland
6No current affiliation
7Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA
8Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
9Texas Children’s Hospital, Houston, TX, USA
10Department Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, USA

Key Words: Berardinelli-Seip syndrome, seipinopathy, congenital generalized lipodystrophy, polyneuropathy, AGPAT2, fat biology.

Corresponding Authors:
Joanna Oswiecimska, M.D., Ph.D.
Medical University of Silesia in Katowice, Department of Pediatrics in Zabrze. 3-go Maja 13-15, 41-800 Zabrze, Poland
Phone: +48 32 37 04 273 / Fax: +48 32 27 18 701 / E-mail: smina@poczta.onet.pl

Pawel Gawlinski, Ph.D.
Institute of Mother and Child, Department of Medical Genetics
Kasprzaka 17A, 01-211 Warsaw, Poland
Phone: +48 22 32 77 299 / Fax: +48 22 32 77 200 / E-mail: pawel.gawlinski@imid.med.pl

Name and address of person to whom reprint requests should be addressed: Pawel Gawlinski (address as above).

Grants or fellowships supporting the writing of the paper: National Science Centre, Poland 2015/19/B/NZ2/01824. Also funded in part by the US National Human Genome Research Institute (NHGRI)/ National Heart Lung and Blood Institute (NHLBI) grant number UM1HG006542 to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG).
Abstract

Primary polyneuropathy in the context of Seip-Berardinelli type 1 seipinopathy, or congenital lipodystrophy type 1 (CGL1) is previously unknown. We report the case history of a 27 year old female CGL1 patient presenting with unusual additional development of non-diabetic peripheral neuropathy (PN) and learning disabilities in early adolescence. Whole exome sequencing (WES) of the patient genome identifies a novel rare variant homozygous for a 52 bp intronic deletion in the AGPAT2 locus uniquely associated with CGL1 seipinopathies, with no molecular evidence for dual diagnosis. Functional studies using RNA isolated from patient peripheral blood leucocytes show abnormal RNA splicing resulting in the loss of 25 amino acids from patient AGPAT2 protein coding sequence. Stability and transcription levels for the misspliced AGPAT2 mRNA in our patient nonetheless remain normal. Any AGPAT2 protein produced in our patient is therefore likely to be dysfunctional. However, formal linkage of this deletion to the neuropathy observed remains to be shown. The classical clinical presentation of a patient with AGPAT2-associated lipodystrophy shows normal cognition and no development of polyneuropathy. Cognitive disabilities and polyneuropathy are features to date associated exclusively with clinical CGL type 2 arising from BSCL2 gene mutations. This case study suggests that in some genetic contexts, AGPAT2 mutations can also produce phenotypes with primary polyneuropathy.

What is already known on this topic?
Within Berardinelli-Seip syndromes (Congenital Lipodystrophy disorders characterized by total absence of both metabolic and mechanical fat tissue), only CGL type 1 retains mechanical fat and is exclusively associated with AGPAT2 gene mutations. Polyneuropathies and learning deficiencies are currently unknown in the context of classical CGL1 disease and AGPAT2 lesions.

What this study adds?
Unusual lifelong 27yr case history of classical CGL1 with mechanical fat retention, featuring developmental polyneuropathy, learning deficiencies, and a new AGPAT2 intronic deletion. Our results describe a phenotype expansion for CGL1 and suggest certain AGPAT2 gene lesions cause neuropathy which blurs clinical presentation boundaries for CGL and other fat biology disorders.

Introduction
Berardinelli-Seip syndrome, also known as congenital generalized lipodystrophy (CGL), occurs in approximately 1 in 10 million of the world population and can result from mutation in 4 genes, giving rise to 4 clinically similar but distinguishable subsyndromes affecting fat biology¹. CGL type 1 (OMIM#608594) is autosomal, recessive and uniquely associated with mutation in the AGPAT2 gene encoding 1-acylglycerol-3-phosphate-O-acyltransferase 2². This enzyme is integral to phospholipid biosynthesis, triglyceride/fat formation and storage, adipocyte formation and fat metabolism pathways and has multiple molecular interaction partners¹.
Clinical symptoms associated with CGL1 to date involve both metabolic malfunctions and physical malformations present in all forms of CGL. Complete lack of all metabolic body fat (adipose tissue that stores energy) is the central clinical characteristic from birth for all forms. CGL1 patients alone, however, retain mechanical fat (adipose tissue that provides protective padding for joints and points of impact i.e. palms, soles of feet, joints, scalp facial bones). This fat distribution is specific and differentially diagnostic for CGL1¹. Clinical neuropathy
and cognitive deficits are associated with CGL2 and mutations in BSCL2, and are rare but not unknown for CGL3 and CGL4 syndromes (associated with CAV1 and PTRF gene mutations respectively\textsuperscript{1,2}). Primary neuropathy and cognitive deficit in the context of CGL1 are previously unreported in the absence of diabetic or other secondary disease complications. We present the natural history of a female CGL1 patient, continuously recorded from infancy to adulthood. We further demonstrate this patient carries a previously unknown homozygous intronic deletion variant g.12562_12613del p.(Val197Glufs*32) in the AGPAT2 gene. Our functional studies show the deletion disrupts normal AGPAT2 transcriptional processing and mRNA coding content consistent with a dysfunctional and therefore potentially pathogenic effect for this deletion.

**Case History**

Table 1 lists clinical symptoms from infancy (3 months) to current age (27 years) in chronological order of emergence.

Family history discloses distant parental consanguinity; identity by descent (IBD) is corroborated by extensive absence of heterozygosity (AOH) totalling 46Mbp, in the patient genome, with an average AOH region size of 321Kbp. The AOH block encompassing the patient AGPAT2 gene is 1.1Mbp (see Methods). Direct ancestors on both sides lived in the same village for many generations. Both parents are clinically asymptomatic for CGL1. One grandfather however presented with lipodystrophy and diabetes mellitus (DM) (Column 4, Table 1).

The patient was born to a 34 year old G5P4->5 mother by spontaneous vaginal delivery. The father was 39 years old. Parents reported an unremarkable prenatal history. Clinical evaluation at patient age of 3 months revealed the presence of numerous dysmorphic and metabolic features associated with CGL (Table 1) including 7 clinical features diagnostic for CGL seipinopathies (1-7, Table 1). Physical examination revealed generalized lipodystrophy, large hands and feet, and enlarged tongue (8-10, Table 1), a low anterior hairline and low set ears (11-12, Table 1), hepatomegaly and an umbilical hernia (13, Table 1).

The patient presents with cardiovascular system abnormalities including concentric hypertrophic cardiomyopathy, with left heart-ventricular enlargement and thickened intraventricular septum detected using imaging techniques (5, Table 1). Heart muscle contractility was good. Abdominal ultra sound showed a hyperechogenic liver (3, Table 1). Pathology evaluation of liver biopsy specimen showed microvesicular steatosis and intertrabecular fibrosis (3, Table 1).

Metabolic abnormalities present from birth included elevated serum triglycerides (4.01 mmol/l, normal range 0.4-1.8 mmol/l), low HDL-C (0.58 mmol/l, normal range 0.9-2.0 mmol/l) Oral glucose tolerance test (OGTT) was normal – fasting glucose was 4.7 mmol/l and after 120 min – 4.7 mmol/l, glycated hemoglobin (HbA1c) – 4.82% (normal range 4.5-6.5%). Other abnormal laboratory studies included mildly elevated serum alanine aminotransferase (ALAT) (50.2 U/l, normal range 0-41 U/l) and high alkaline phosphatase (ALP) levels (351 U/l, normal range 20-150 U/l) levels. All of these metabolic imbalances except elevated alkaline phosphatase, are progressive conditions (1-6, Table 1).

At age 7 years our patient displayed acanthosis nigricans on the nape of the neck and in axillary and popliteal regions and prominent musculature, due to general absence of metabolic fat tissue and abnormal fat deposition in muscles, (14-17, Table 1). At this age we noted that despite absence of metabolic fat, mechanical fat tissue was maintained. We also found accelerated linear growth velocity, concomitant with accelerated skeletal maturation of 2
years. Serum concentration for growth hormone was low and an MRI scan of the hypophysis was normal. Gigantism was not observed, despite the appearance of acromegaloïd features. At age 14, neurological symptoms (18-22, Table 1) began to emerge. Learning disability (IQ score 88) (18, Table 1) was first noted at this age. We also noted acroparaesthesiae of both hands (19, Table 1). In addition we found changes in electromyogram (EMG) tracings, mildly reduced neurogenic pattern and decreased motor fibre nerve conduction velocity (NCV) in median, sural and peroneal nerves; also for sensory fibres in median and sural nerves (20-22, Table 1). MRI scans however showed no sign of median nerve compression. Normal serum calcium phosphorus, magnesium, and parathormone concentrations further excluded hypoparathyroidism.

At age 16, the patient presented with multiple endocrine abnormalities. In addition, at 16 years, a number of clinical features emerged relating to hormonal disturbances (23-30, 32 Table 1). She presented with primary amenorrhoea with clinical and laboratory assay symptoms of hyperandrogenism (clitoral enlargement and free testosterone 11.33 pg/ml, normal range 1.1-6.3 pg/ml, androstenedione 3.60 ng/ml, normal range 0.8-2.4 ng/ml, respectively) were noted (28,30 Table 1). Sonographic evaluation showed atrophic ovaries with no ovarian follicles (28, Table 1). Hirsutism was also first noted (32, Table 1). Hormonal function of the hypophysis was normal. The patient also presented with diabetes mellitus (DM) (27, Table 1) identified on the basis of an OGTT (0 min – 3.7 mmol/l; 120 min – 11.9 mmol/l) with a high homeostasis model assessment of insulin resistance value (10.39). HbA1c was 4.6%.

Current status: At 27 years, our patient has graduated from college and is employed as a clerk in an office. Paraesthesiae of the hands has not aggravated since first appearance. Diabetes is well-controlled (HbA1c – 5.1%), but dyslipidemia persists despite aggressive therapy (serum triglycerides – 3.8 mmol/l; HDL-C – 0.29 mmol/l). Current medications include metformin (3 g/day), fenofibrate (267 mg/day), rosuvastatin (10 mg/day) and insulin (1.5 UI/kg/day).

Molecular analyses

WES analysis reveals a homozygous 52 bp intronic deletion, g.12562_12613del p.(Val197Glufs*32), affecting the 5’splice site for exon 5 of the AGPAT2 gene. Bioinformatic prediction software (MutationTaster) indicates the deletion (g.12562_12613del) is of unknown pathogenicity. This variant is absent from the ExAC and 1000G databases. No rare variant alleles in other known disease associated genes were found which could potentially explain the lipodystrophy phenotype or the neuropathy observed in our patient3. Sanger sequencing confirmed the AGPAT2 deletion variant and cosegregation with the disease trait according to Mendelian expectations (Figure 1A), and also showed the expected reference sequence around the deletion at the nucleotide level (Figure 1B). This shows the patient is homozygous for the g.12562_12613del p.(Val197Glufs*32) allele. Also, each clinically asymptomatic parent is heterozygous for the identical variant allele (Figure 1C-D). Standard PCR (Figure 1E, upper image) on genomic template DNA from both patient and parents generates a PCR product shorter (red arrowhead) than the wildtype (grey arrowhead), consistent with a 52 bp genomic deletion. Standard PCR on cDNA templates (lower image) reveals a PCR product shorter by 75 bp for the patient AGPAT2 mRNA (red arrow) relative to the wildtype control individual mRNA (grey arrowhead). Direct Sanger sequence of the cDNA PCR products shows complete deletion of exon 5 (75 bp), leaving exon 4 joined to exon 6 with frameshifted coding sequence downstream of the join creating a premature translation stop signal. The parents are each heterozygous for the deletion and generate both forms of mRNA, and therefore show both mutated and wildtype PCR products (Figure 1E, mother, father).
To assess mutant \textit{AGPAT2} mRNA expression levels and/or stability we used Real Time PCR (RT PCR) to quantify mutant and WT \textit{AGPAT2} mRNA. Expression levels of \textit{AGPAT2} mRNA generated from patient (homozygous for deletion allele) and both parent (heterozygous for deletion allele) mRNA samples are comparable to those of a healthy control individual (homozygous for wildtype allele) (Figure 1F). Stability and/or transcription levels therefore appear unaffected for the mutant mRNA. We conclude \textit{AGPAT2} mRNA expression levels and stability in our patient remain unaffected by this deletion.

\textbf{Methods:}

Genomic DNA samples were isolated from blood leucocytes from each individual. Copy number variations (CNV) were identified using array Comparative Genomic Hybridization (aCGH) and bioinformatic analyses using XHMM\textsuperscript{4} and HMZDelFinder\textsuperscript{5} algorithms; single nucleotide variation (SNV) was determined by WES analysis\textsuperscript{6}, and confirmed by Sanger sequencing. Chromosomal regions demonstrating absence of heterozygosity (AOH) were detected by analyzing B-allele frequency data obtained from WES\textsuperscript{6} by running BafCalculator\textsuperscript{7} (https://github.com/BCM-Lupskilab/BafCalculator). \textit{AGPAT2} expression was measured by quantitative real-time polymerase chain reaction (RT PCR) (TaqMan Gene Expression Assay for \textit{AGPAT2} gene (Life Technologies, Grand Island, NY, USA), on blood lymphocyte mRNA isolated using High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Grand Island, NY, USA). Level of \textit{AGPAT2} expression is corrected to the mRNA level of housekeeping genes \textit{GAPDH} and \textit{TBN}. Expression data reflect means of three independent experiments each performed in triplicate.

Primers and probes:

gDNA PCR
F: CTCACTGGCTTCTGAGATGG; R: GGTCCATCCGTGTGAAGTCT

cDNA PCR
F: GGGAGAACCTCAAAGTGTGG; R: GGTCTTGGAGATGTGGAGGA

RT PCR
TaqMan Gene Expression Assay, Thermofisher labelled probes cat.no. HS00944961.

Study approval: Bioethics Committee for Institute of Mother and Child, Warsaw. Informed consent was obtained from the patient and her parents.

\textbf{Discussion}

The detailed, lifelong clinical case history reveals findings diagnostic for Berardinelli-Seip syndrome from infancy. Childhood mechanical fat distribution differentially diagnostic for CGL1, in this case however, was followed by development of polynuropathy and cognitive disability in early adolescence, symptoms not previously reported in CGL1 patients. Intellectual disability is typical for CGL2 and rare in other forms of CGL. Primary neuropathy in the absence of diabetes mellitus complications leading to neural pathology, is associated with CGL2 but is to date, not reported for CGL1. Polynuropathy is associated with a range of lipodystrophic disorders (AKINCI ref here), but in CGL1 patients, the neuropathy reported to date arises from diabetic complications or other secondary conditions. In our patient, laboratory test evidence of diabetes was only found 2 years after initial development of neuropathy. The polynuropathy observed here is therefore unlikely to be a diabetic complication. (EMG/NCV) results (see 20-21 Table 1) suggest demyelinating neuropathy similar to that caused by duplications in the \textit{PMP22} gene responsible for Charcot-Marie Tooth type 1A syndrome. However, no \textit{PMP22} duplication was detected, nor were any recessive CMT genes found to map within AOH intervals. The possibility that elevated patient triglyceride levels contribute to the clinical manifestation of peripheral neuropathy however, cannot be excluded.
All forms of CGL involve complete lack of metabolic fat (body fat) from birth and the majority show early presentation of severe hypertriglyceridemia, hepatic steatosis, hepatosplenomegaly, acanthosis nigricans and insulin resistance, generally leading to diabetes in early adolescence. Enlargement of liver tissue and slightly enlarged hands and feet are also typical. Myocardiopathies arise in approximately 25% of individuals. The emergence at age 16 in our patient, of multiple symptoms related to hormonal disturbances after puberty (eg. polycystic ovarian syndrome and hyperinsulinemia) is also typical for all Berardinelli-Seip syndromes including CGL1. Our patient presents with all these CGL-associated symptoms by early-mid adolescence, with concomitant emergence of neuropathological symptoms and learning disability in early adolescence. In addition, umbilical hernia, present in our patient at 3 months, was found by one study to be associated only with BSCL2 mutations9. The clinical picture therefore suggests CGL2, despite the normal mechanical fat distribution differentially diagnostic for CGL11.

Our genomic investigation nonetheless confirms a previously unknown, single exon, homozygous 52bp deletion in AGPAT2; a gene uniquely associated with CGL1 seipinopathy. Given the inability to identify any other known disease genes that might explain the unusual phenotypic features (i.e. polyneuropathy, cognitive deficiency) associated with known bona fide AGPAT2-related CGL1 clinical manifestations in this patient – we suggest a potential phenotypic expansion. Whether this new mutation causes the neuropathology observed however, remains unresolved. Our molecular analyses show the intronic 5’ splice site deletion eliminates 25 codons of protein coding sequence and generates a frameshift resulting in a premature translation stop codon. There is no evidence for mutant AGPAT2 mRNA instability in the blood cell studies. Structure and function of any AGPAT2 protein in our patient however would likely be impaired.

Precisely how this would affect physiological pathways involving AGPAT2 is unknown. The AGPAT2 protein is located in the membrane of the endoplasmic reticulum, and is primarily involved in triglyceride and phospholipid biosynthesis, with multiple interaction partners involved in lipid biosynthesis/degradation and related pathways including acyl chain remodelling of phosphatidylethanolamine (PE)10, adipose droplet formation, lipid signalling and ER and mitochondrial membrane transport pathways11,12. Many CMT neuropathy genes involve this transport biology, hinting at possible overlapping molecular bases12 for the polyneuropathy observed in this patient. Disruption of post-translational protein-protein interactions central to lipid homeostasis and of related pathway function, such as cholesterol metabolism, are highly probable and likely to have fundamental physiological effects. Other mutations leading to similar disequilibrium of lipid homeostasis, phospholipid degradation and remodelling in ER and mitochondrial membranes for example, have been linked to neural degeneration and epileptic seizures in flies and worms, with similar phenotypes for mutations in human gene counterparts13. Disruption of phospholipid homeostasis is also linked to α-synuclein protein aggregation implicated in Parkinson Disease pathology11,14. Disrupted cholesterol metabolism, also, is linked to protein aggregation leading to mitochondrial distribution defects and neurodegenerative disease13,14.

We remark that known AGPAT2 regulatory circular RNA (circRNAs; non-coding post-transcriptional splicing products) expression levels are high in normal foetal tissues, including adrenal tissue, which regulates circulating hormonal levels in the developing foetus12,13. Recent elucidation of fundamental functions for circular regulatory RNA in eukaryotic gene expression programs14 highlights the potential for future investigations into defective RNA processing during foetal development as a possible contributor to genetic disorders.
Finally, an epidemiological note: \textit{AGPAT2} mutations predominate in American CGL cases of African descent. The vast majority of European seipinopathies arise from mutations in \textit{BSCL2}. The newly identified \textit{AGPAT2} deletion in our patient is located within a large block (approximately 1.1Mb) of AOH (chromosome sequence with both alleles identical at nucleotide sequence level) (Figure 1, C-D). Blocks of AOH arise when parentage is related, as is the case for this patient. The rare deletion in \textit{AGPAT2} we identify appears to have arisen in an individual of a small European village and accumulated in the local population over generations.

In short, this work documents the first report of primary polyneuropathy within the classical clinical CGL1 syndrome exhibiting differentially diagnostic mechanical fat retention, establishing a potential phenotypic expansion for CGL1 disease. We further identify a new, recessive intronic splice site deletion in the CGL1-associated \textit{AGPAT2} locus, resulting in an apparently translatable truncated mRNA species with missense coding. Precisely how the splicing defect identified affects \textit{AGPAT2} protein physiology or noncoding transcriptional regulatory RNA functions remains undefined. This however, is the case for all \textit{AGPAT2} mutations linked to CGL1 phenotype: the mechanism of action has not been defined for any.

\textbf{Acknowledgement, Conflict of Interests and Source of Funding:}
J.R.L. has stock ownership in 23andMe and is a paid consultant for Regeneron. J.R.L. is a coinventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the chromosomal microarray analysis (CMA) and clinical exome sequencing offered at Baylor Genetics (MGL; http://www.bcm.edu/geneticlabs/). The other co-authors declare that they have no conflict of interest. Study support: National Science Centre, Poland 2015/19/B/NZ2/01824. Also funded in part by the US National Human Genome Research Institute (NHGRI)/National Heart Lung and Blood Institute (NHLBI) grant number UM1HG006542 to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG).

\textbf{Input for authorship (according to ICMJ recommendations):}
1 - Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; 2 - Drafting the work or revising it critically for important intellectual content; 3 - Final approval of the version to be published; 4 - Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Joanna OŚwięcimska - 1, 2, 3
Mateusz Dawidziuk - 1
Tomasz Gambin – 1, 2, 3
Katarzyna Ziora - 3
Marta Marek - 1
Sylwia Rzońca - 1
D. Lys Guilbride – 2, 3
Shalini N. Jhangiani - 1
Anna Obuchowicz – 1, 2
James R. Lupski – 1, 3
Alicja Sikora – 1
Wojciech Wiszniewski – 1, 2
Pawel Gawlinski – 1, 2, 3, 4

\textbf{References}


Figure 1. (A) Patient pedigree for homozygous AGPAT2 deletion mutation c.589-55_589-4del p.(Val197GluFS*32). (B) Sanger sequence confirmation of biparental inheritance for the mutation. Black arrow shows point of deletion. (C) Genomic context of AGPAT2 mutation. Cartoon shows Chromosome 9 organization. Grey blocks denote regions with absence of heterozygosity (AOH). Scattered dots indicate SNV for proband along chromosome 9. Absence of SNV in centromere-adjacent areas reflects lack of reference sequence for these region. (D) Detail for AOH region surrounding the AGPAT2 mutation (vertical red line at around 13,958,000 base pair). (E) PCR products for AGPAT2 in patient (mutation homozygous), each parent (mutation heterozygous) and control individual (wildtype)
homozygous). Red arrowhead, reduced AGPAT2 product size reflecting deletion mutation. Grey arrowhead, normal size wildtype AGPAT2 product. Genomic gDNA template, upper image; complementary cDNA template lower image. (F) RT PCR products for AGPAT2 mRNA expression levels in patient, parents and control are comparable. NS: nonsignificant.

**Table 1. Developmental timeline for clinical emergence of Seip-Berardinelli syndrome and neuropathology features in our patient.**

<table>
<thead>
<tr>
<th>#</th>
<th>FEATURES</th>
<th>HPO no.</th>
<th>Age at emergence</th>
<th>Familial features (Grandfather)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Congenital generalized lipodystrophy x</td>
<td>HP:0009059</td>
<td>+++ 3 m ●</td>
<td>+++ ▲</td>
</tr>
<tr>
<td>2</td>
<td>Hypertriglyceridemia</td>
<td>HP:0002155</td>
<td>+++ 3 m ●</td>
<td>Nd</td>
</tr>
<tr>
<td>3</td>
<td>Hepatomegaly x</td>
<td>HP:0002240</td>
<td>++ 3 m ●</td>
<td>Nd</td>
</tr>
<tr>
<td>4</td>
<td>Hepatic steatosis x</td>
<td>HP:0001397</td>
<td>++ 3 m ●</td>
<td>Nd</td>
</tr>
<tr>
<td>5</td>
<td>Concentric hypertrophic cardiomyopathy x</td>
<td>HP:0005157</td>
<td>++ 3 m ●</td>
<td>Nd</td>
</tr>
<tr>
<td>6</td>
<td>Elevated hepatic transaminases (ALAT)</td>
<td>HP:0002910</td>
<td>+ 3 m ●</td>
<td>Nd</td>
</tr>
<tr>
<td>7</td>
<td>Elevated alkaline phosphatase</td>
<td>HP:0003155</td>
<td>+ 3 m</td>
<td>Nd</td>
</tr>
<tr>
<td>8</td>
<td>Large hands x</td>
<td>HP:0001176</td>
<td>+ 3 m</td>
<td>Nd</td>
</tr>
<tr>
<td>9</td>
<td>Large feet x</td>
<td>HP:0001833</td>
<td>+ 3 m</td>
<td>Nd</td>
</tr>
<tr>
<td>10</td>
<td>Increased size of tongue</td>
<td>HP:0000158</td>
<td>+ 3m</td>
<td>Nd</td>
</tr>
<tr>
<td>11</td>
<td>Low anterior hairline</td>
<td>HP:0000294</td>
<td>+ 3m</td>
<td>Nd</td>
</tr>
<tr>
<td>12</td>
<td>Lowset ears</td>
<td>HP:0000369</td>
<td>+ 3m</td>
<td>Nd</td>
</tr>
<tr>
<td>13</td>
<td>Umbilical hernia x</td>
<td>HP:0001537</td>
<td>+ 3m</td>
<td>Nd</td>
</tr>
<tr>
<td>14</td>
<td>Acanthosis nigricans x</td>
<td>HP:0000956</td>
<td>+++ 7 y ●</td>
<td>+++ ▲</td>
</tr>
<tr>
<td>15</td>
<td>Accelerated skeletal maturation x</td>
<td>HP:0005616</td>
<td>+7y</td>
<td>Nd</td>
</tr>
<tr>
<td>16</td>
<td>Accelerated linear growth x</td>
<td>HP:000098</td>
<td>+7y</td>
<td>Nd</td>
</tr>
<tr>
<td>17</td>
<td>Abnormality of the musculature x</td>
<td>HP:0003011</td>
<td>+ 7 y</td>
<td>Nd</td>
</tr>
<tr>
<td>18</td>
<td>Intellectual disability</td>
<td>HP:0001256</td>
<td>+ 14 y</td>
<td>Nd</td>
</tr>
<tr>
<td>19</td>
<td>Acroparesthesia (hands)</td>
<td>HP:0031006</td>
<td>+ 14 y</td>
<td>Nd</td>
</tr>
<tr>
<td>20</td>
<td>Electromyography (EMG): neuropathic changes</td>
<td>HP:0003445</td>
<td>+ 14 y</td>
<td>Nd</td>
</tr>
<tr>
<td>21</td>
<td>Decreased motor nerve conduction velocity (NCV)</td>
<td>HP:0003431</td>
<td>+ 14 y (median nerve and peroneal nerves)</td>
<td>Nd</td>
</tr>
<tr>
<td>22</td>
<td>Decreased sensory NCV</td>
<td>HP:0003448</td>
<td>+ 14 y (median and sural nerves)</td>
<td>Nd</td>
</tr>
<tr>
<td>23</td>
<td>Amenorrhea x</td>
<td>HP:0000141</td>
<td>+++ 16 y</td>
<td>Na</td>
</tr>
<tr>
<td>24</td>
<td>Polycystic ovarian syndrome x</td>
<td>HP:0000147</td>
<td>+++ 16 y</td>
<td>Na</td>
</tr>
<tr>
<td>25</td>
<td>Hypoplasia of the ovary</td>
<td>HP:0008724</td>
<td>+++16 y</td>
<td>Na</td>
</tr>
<tr>
<td>26</td>
<td>Hyperinsulinemia x</td>
<td>HP:0000842</td>
<td>+++ 16 y</td>
<td>Nd</td>
</tr>
<tr>
<td>27</td>
<td>Noninsulin-dependent diabetes mellitus x</td>
<td>HP:0005978</td>
<td>++ 16 y ●</td>
<td>++ ▲</td>
</tr>
<tr>
<td>28</td>
<td>Increased circulating androgen level</td>
<td>HP:0030348</td>
<td>++ 16 y</td>
<td>Nd</td>
</tr>
<tr>
<td>29</td>
<td>Labial hypertrophy</td>
<td>HP:0000065</td>
<td>++ 16 y</td>
<td>Na</td>
</tr>
<tr>
<td>30</td>
<td>Clitoromegaly x</td>
<td>HP:0008665</td>
<td>++ 16 y</td>
<td>Na</td>
</tr>
<tr>
<td>31</td>
<td>Weakness of the intrinsic hand muscles (asymmetric)</td>
<td>HP:0009005</td>
<td>+ 16 y</td>
<td>Nd</td>
</tr>
<tr>
<td>32</td>
<td>Hirsutism x</td>
<td>HP:0001007</td>
<td>+ 16 y</td>
<td>Nd</td>
</tr>
</tbody>
</table>

Seip-Berardinelli symptoms are shown on white background, **primary** neuropathologies are shaded grey.; HPO no., Human Phenotype Ontology database identification number for
phenotypic abnormality. ; EMG, electromyogram; NCV, nerve conduction study. Symbols: 
+++ , strong presentation; ++ , medium presentation; + , mild presentation; nd, no data; na, not 
applicable; y, years; m, months; ●, progressive condition; ▲, age at emergence unknown.; x-
diagnostic for CGL1.